Zymeworks, Inc., based in the United States, is a pharmaceutical company with an ESG score of 29.0, indicating a medium risk. Specializing in the development of multifunctional biotherapeutics, Zymeworks is focused on producing innovative treatments for patients with solid tumors expressing HER2. With a clinical candidate, zanidatamab, in multiple stages of evaluation, the company is also advancing a diverse pipeline in oncology and other areas.